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Dr Frank Sellke (Boston, Mass). That was a nice study. My
question is kind of generic. You mentioned in the beginning of
your talk that there have been approximately 10,000 studies show-
ing benefit in laboratory animals, yet when it goes to the clinic, very
few, if any, really show any promise. Why is that?
DrMoss.Well, I think there are many factors. One is timing. It is
really surprising, but actually when you start reading all of those
studies, you will find that the majority of inhibitors are given before
ischemia or during ischemia, a time for us that isn’t clinically rele-
vant. You can’t really pinpoint what is going to happen during that
time, and the time of reperfusion, when the stent is placed or when
you come off clamp, is the one thing that we do know. Unfortu-
nately, temporally relevant conditions haven’t really been studied
that much, and so that was one of the points of this article. It is al-
most more conceptual, I think. The point of this article is that we
really need to pin down exactly what we are translating into clinical
practice, because it may not work if you do it a different way in
those animal studies.
Then also, for example, one limitation of this study is that these
are healthy 8-week-old C57 black six mice. These aren’t knockout
or like apolipoprotein E, and they develop atherosclerosis like you
might find in the person undergoing CABG. They are not obese or
diabetic. I think we need to have more studies that look at a multi-
factorial animal, because it may not work. Although it might work
in a healthy animal, it may not work in one that is diabetic or has
other comorbidities.diovascular Surgery c Volume 136, Number 5 1279
